HIV Therapeutics Made From Scytovirins
Background:
The National Cancer Institute and
Molecular Targets Development Program is seeking statements of
capability or interest from parties interested in collaborative
research to obtain pre-clinical data to be used to further develop,
evaluate, or (more...)
(Full Text)
Griffithsin, a Novel anti-HIV Protein with Potential Microbicidal, Therapeutic and/or Purification Utilities
Background:
The National Cancer Institute
(NCI) Molecular Targets Development Program (MTDP) seeks a
Cooperative Research and Development Agreement (CRADA) collaborator
to develop griffithsin (GRFT), a novel, potent anti-HIV protein
isolated from an aqueous extract of (more...)
(Full Text)
Imaging Agents to Monitor the Distribution of Therapies Delivered to the Brain
Background:
The National Institute of
Neurological Disorders and Stroke (NINDS) seeks a commercial
collaborator to work with NINDS in the development and
commercialization of surrogate markers for monitoring the spatial
distribution of therapeutic substances by (more...)
(Full Text)
Potential Compounds for the Prevention and Treatment of Skin Tumors
Background:
The Laboratory of Cellular
Carcinogenesis and Tumor Promotion at the National Cancer Institute
(NCI), NIH is seeking collaborative partners to further develop
methods and pharmaceutical compounds for the prevention and
treatment of skin tumors. (more...)
(Full Text)
Chemotoxins: Specific Killers of Cancer Cells and Other Cells
Background:
The National Institute on Aging's
Laboratory of Immunology demonstrated that chemokines can be used
to deliver tumor antigens to dendritic cells and elicit anti-tumor
responses. The Lab is seeking Cooperative Research and Development
Agreement (more...)
(Full Text)
2nd -Generation, NO-Releasing Non-Steroidal Anti-Inflammatory Prodrugs
Background:
The Laboratory of Comparative
Carcinogenesis at the National Cancer Institute is seeking
statements of capability, or interest, from parties interested in
collaborative research to further develop, evaluate, and/or
commercialize new and safer analgesic, anti-inflammatory,
anti-thrombotic, (more...)
(Full Text)
Anti-neoplastic Agents as Cancer Therapy or Dermatologic Agents
Background:
The National Cancer Institute's
Structural Biophysics Laboratory is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize
anti-neoplastic agents based on peptide and peptidomimetic
inhibitors of (more...)
(Full Text)
Inhibitor for the Diagnosis and Treatment of Metastatic Cancer
Background:
The National Cancer Institute's
Laboratory of Population Genetics is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize screening
markers for early diagnosis of metastasis. (more...)
(Full Text)
A Therapeutic Target for Inherited Form of Cushing Syndrome and Endocrine Tumors (PDE11A MUTATIONS IN ADRENAL DISEASE)
Background:
Cushing Syndrome, a disorder
associated with excess production of cortisol affects up to 10 per
15 million people every year. Cushing Syndrome may be caused by
several reasons such as cortisol-producing endocrine tumors (more...)
(Full Text)
Anakin Protein as a Prognostic Tool for Diagnosing Breast Cancer Outcome
Available for collaborative research toward commercial
development and/or exclusive and non-exclusive
licensing:
Method of diagnosis for early metastasis and
therapeutic inhibition of metastasis.
Nucleic acid sequence of Anakin protein, an
extracellular matrix (ECM) modifier gene.
SiRNA sequences (more...)
(Full Text)
Biomarker to Predict Resistance to Doxorubicin Cancer Therapy
Background:
The Laboratory of Human
Carcinogenesis, Center for Cancer Research, National Cancer
Institute, National Institutes of Health, is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or (more...)
(Full Text)
Novel Therapeutics for the Treatment and Prevention of Avian Influenza
Background:
The National Cancer Institute is
seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize cyanovirin-N for use against H5N1 influenza. The
technology is also available (more...)
(Full Text)
Fenoterol Analogues for Treating Congestive Heart Failure
Background:
The Laboratory of Clinical
Investigation of the National Institute of Aging is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize fenoterol analogues and their (more...)
(Full Text)
Treatment of Cocaine Abuse and Other Mental Disorders
Background:
The Medicinal Chemistry and
Psychobiology Sections, National Institute on Drug Abuse-Intramural
Research Program, National Institutes of Health, is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, (more...)
(Full Text)
CCR5-Specific Human Monoclonal Antibodies for HIV
Background:
Antibodies are available for
collaborative research toward commercialization and/or exclusive
and non-exclusive licensing. In vitro data is available at this
time.
Technology:
The HIV co-receptor CCR5 has been
demonstrated to play an important role in virus (more...)
(Full Text)
Identification of T-Cell Receptors (TCR)
Background:
The NIH National Cancer
Institute's Surgery Branch seeks a research partner to further
develop, evaluate, or commercialize adoptive immunotherapy
therapeutics under a Collaboration Agreement or a Cooperative
Research and Development Agreement (CRADA).
Technology:
Adoptive immunotherapy
circumvents a (more...)
(Full Text)
Angio-inhibitory Peptides Derived from Human TIMP-2
Background:
The National Cancer Institute
(NCI) is currently seeking cooperative partners to work with
investigators in the Center for Cancer Research (CCR) to exploit,
for drug development and clinical testing, novel TIMP-2
peptide-based inhibitors of (more...)
(Full Text)
HIV-1 Nucleocapsid-p7 Protein-Nucleic Acid Antagonists as HIV Treatment
The National Cancer Institute
(NCI)-Developmental Therapeutics Program (DTP) - Screening
Technologies Branch (STB, in collaboration with the NCI-Retroviral
Assembly and Protein Chemistry Laboratories and the AIDS Vaccine
Program), have identified several classes of lead (more...)
(Full Text)
A New Series of Thalidomide Analogs with Potent Anti-Angiogenic and Anti-Cancer Properties
Background:
The Medical Oncology Branch of
the National Cancer Institute seeks a Cooperative Research and
Development Agreement (CRADA) collaborator for preclinical and
clinical development of thalidomide analogs.
The classical orally active drug, thalidomide
(N-alpha-phthalimidoglutarimide), a glutamic (more...)
(Full Text)
Treating Squamous Cell Cancer Using Beta-Catenin Splice Variants
Background:
The National Cancer Institute,
Division of Cancer Epidemiology and Genetics is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize a method of
treating cancer (more...)
(Full Text)
Development of Novel Anti-Hiv Compounds
Background:
The HIV DRP Retroviral
Replication Laboratory at the National Cancer Institute-Frederick
is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize active anti-viral compounds. The (more...)
(Full Text)
Treatment of Cocaine-Induced Fetal Brain Injury
Description of
Technology:
The Cellular Neurobiology
Research Branch of the National Institute on Drug Abuse is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize the development (more...)
(Full Text)
Method of Treating or Preventing Oxidative Stress-Related Diseases
Background:
The National Institute on Aging,
Laboratory of Neurosciences is seeking statements of capability or
interest from parties interested in collaborative research to
further develop, evaluate, or commercialize a uric acid analogue
for the treatment (more...)
(Full Text)
Inhibitors for Metastasized Breast Cancers
Background:
The National Cancer Institute's Laboratory of
Molecular Pharmacology is seeking statements of capability or
interest from parties interested in collaborative research to
further develop, evaluate, or commercialize histone deacetylase
(HDAC) inhibitor (HDI) for breast (more...)
(Full Text)
Biomarkers for Diagnosis and Treatment of Hepatocellular Carcinoma (HCC)
Background:
The Molecular Genetics and
Carcinogenesis Section of the National Cancer Institute is seeking
statements of capability or interest from parties interested in
collaborative research to obtain pre-clinical developmental data to
be used to further (more...)
(Full Text)
Antisera to Detect Phosphorylated Phosphoinositide-Dependent Kinase 1 (PDK-
Background:
The National Institutes of
Health, National Center for Complementary and Alternative Medicine,
Diabetes Unit is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize phospho-specific (more...)
(Full Text)
Recombinant Anti-mesothelin Immunotoxin SS1P (anti-mesothelin dsFv-PE38) as a Therapeutic Agent and Diagnostic Tool for Multiple Cancer Types
Background:
The National Cancer Institute's
Laboratory of Molecular Biology is seeking statements of capability
or interest from parties interested in collaborative research to
further develop or commercialize the anti-mesothelin immunotoxin
SS1P as an anti-tumor agent. (more...)
(Full Text)
Cancer Treatment Using Inhibitors of Tyrosyl-Dna Phosphodiesterase (Tdp1)
Background:
The National Cancer Institute's
Laboratory of Molecular Pharmacology is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize inhibitors
of Tyrosyl-DNA phosphodiesterase (Tdp1). The technology (more...)
(Full Text)
Potential Therapeutic Agents for the Treatment of Metastatic Cancer
Summary of
Technology:
The NIH Surgery Branch seeks a
Cooperative Research and Development Agreement (CRADA) research
partner to further develop, evaluate, or commercialize cancer
therapeutics. T cell receptors (TCR) are the proteins responsible
for the T (more...)
(Full Text)
Gene Therapy to Treat Lung Cancer
Background:
The National Institute of Child
Health and Human Development is seeking statements of capability or
interest from parties interested in collaborative research to
obtain pre-clinical data to be used to further develop, evaluate,
or (more...)
(Full Text)
Wip1 Peptide Inhibitors as Cancer Therapeutics
Background:
The National Cancer Institute's
Laboratory of Cell Biology is seeking statements of capability or
interest from parties interested in collaborative research to
further develop, evaluate, or commercialize Cyclic Phosphopeptide
Inhibitors of Protein Phosphatase 2C (more...)
(Full Text)
Methods of Glycosylation and Bioconjugation
Background:
The National Cancer Institute's
Structural Glycobiology Laboratory is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, and/or commercialize methods
of glycosylation and bioconjugation that can be (more...)
(Full Text)
Oligonucleotides Which Specifically Bind Retroviral Nucleocapsid Proteins
Background:
The Retroviral Replication Lab at
the National Cancer Institute is seeking statements of capability,
or interest, from parties interested in collaborative research to
further develop, evaluate, and/or commercialize oligonucleotides
which bind retroviral nucleocapsid proteins (more...)
(Full Text)
Nitroxide Radical as a Treatment for Neurodegeneration
Background:
The Human Iron Metabolism Section
of the National Institute of Child Health and Human Development
(NICHD) is seeking statements of capability or interest from
parties interested in collaborative research to obtain pre-clinical
data to (more...)
(Full Text)
CD4-Nanoparticle Conjugates for the Treatment of HIV/AIDS
Background:
The Laboratory of Cell Biology of
the National Cancer Institute is seeking statements of capability
or interest from parties interested in collaborative research to
further develop, evaluate, or commercialize polyvalent antiviral
dendritic conjugates for (more...)
(Full Text)
A New Technology for Identification of Hypoxia-Dependent Transcriptional Activation
Background:
The Screening Technologies Branch
of the National Cancer Institute is seeking statements of
capability or interest from parties interested in collaborative
research to obtain pre-clinical data to be used to further develop,
evaluate, or (more...)
(Full Text)
Selenocysteine Enables a New Platform for Immunoconjugates
The Experimental
Transplantation and Immunology Branch of the National Cancer
Institute is seeking statements of capability or interest from
parties interested in forming a collaborative research alliance to
further develop, evaluate, or commercialize a new
platform technology (more...)
(Full Text)
An Improved Non-Viral Gene Therapy System
Background:
The National Cancer Institute's
Nanobiology Program is seeking statements of capability or interest
from parties interested in collaborative research to further
develop, evaluate, or commercialize a tumor-specific gene therapy
agent. The technology is also (more...)
(Full Text)
Cancer Inhibitors Isolated from an African Plant
Background:
The National Cancer Institute's
Molecular Targets Development Program is seeking statements of
interest from parties interested in collaborative research to
further develop, evaluate, or commercialize cancer inhibitors
isolated from the African plant Phyllanthus englerii. (more...)
(Full Text)
Novel Cancer Treatment Methods Using Angiogenesis Inhibitors
Background:
The National Cancer Institute's
Cell and Cancer Biology Branch, Laboratory of Extracellular Matrix
Pathology is seeking statements of capability or interest from
parties interested in collaborative research and/or partnership
agreements to further develop and (more...)
(Full Text)
VEGF-B as a Therapeutic Agent for Neurodenerative Disease
Background:
The National Institutes of
Health's National Eye Institute is seeking statements of capability
or interest from parties to form a collaborative research alliance
to further develop VEGF-B as a Therapeutic Agent for
Neurodegenerative Disease.
Technology:
The (more...)
(Full Text)
Nanoantibodies as Therapeutics and Diagnostics
Background:
The National Cancer Institute
Center for Cancer Research Nanobiology Program is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize nanoantibodies as therapeutics or diagnostics.
The (more...)
(Full Text)
Human Monoclonal Antibody Against Mesothelin
Background:
The National Cancer Institute's
Nanobiology Program is seeking statements of capability or interest
from parties interested in collaborative research to further
develop, evaluate, or commercialize human antibodies that act
against mesothelin.
NIH inventors have demonstrated (more...)
(Full Text)
Human and Improved Murine Monoclonal Antibodies Against CD22
Background:
The National Cancer Institute's
Nanobiology Program is seeking statements of capability or interest
from parties interested in collaborative research to further
develop, evaluate, or commercialize human monoclonal antibodies
expressed in types of lymphoma.
CD22 is (more...)
(Full Text)
Novel Agent to Promote Lung Development and Treat Lung Disease
Background:
The National Cancer Institute's
Laboratory of Metabolism is seeking statements of capability or
interest from parties interested in collaborative research to
further develop, evaluate, or commercialize a novel lung-enriched
cytokine-like molecule as a clinical (more...)
(Full Text)
Anti-Cancer Agents that Inhibit Cell Motility, Angiogenesis, and Metastasis
Background:
The National Cancer Institute's
Urologic Oncology Branch is seeking statements of capability or
interest from parties interested in collaborative research to
further develop, evaluate, or commercialize anti-cancer
drugs.
Technology:
The Grb2 protein, through its SH2
domain, mediates (more...)
(Full Text)
Anti-HIV Nucleoside Analogs
Background:
The National Cancer Institute's
HIV Drug Resistance Program is seeking statements of capability or
interest from parties interested in collaborative research to
further develop, evaluate, or commercialize drugs with activity
against HIV-1.
Technology:
This invention describes (more...)
(Full Text)
Agents that Prevent Gene Silencing and Allow for Long Term Expression of Transgenes
Background:
The National Cancer Institute's
Laboratory of Molecular Pharmacology is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize
gamma-satellite DNA insulators for stable transgene
expression.
Technology:
Introduction of (more...)
(Full Text)
Novel Treatment for Melanoma and Other Pigmentary Disorders
Background:
The National Cancer Institute's
Laboratory of Cell Biology is seeking statements of capability or
interest from parties interested in collaborative research to
further develop, evaluate, or commercialize the regulation of SOX9
function as a (more...)
(Full Text)
Therapeutics and Diagnostics for Non-Small Cell Lung Cancer (NSCLC)
Background:
The National Cancer Institute's
Center for Cancer Research, Laboratory of Human Carcinogenesis is
seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize unique genetic changes (more...)
(Full Text)
Method To Treat Numerous Dermatological Conditions
Background:
The National Cancer
Institute's Laboratory of Cell Biology is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize the use of
DKK1 to treat abnormal (more...)
(Full Text)
Novel Cancer Immunotherapy Approaches For The Treatment And Prevention Of Cancer
Background:
The National Cancer Institute's Laboratory of
Tumor Immunology and Biology is seeking statements of capability or
interest from parties interested in collaborative research to
further develop, evaluate, or commercialize cancer immunotherapy
using costimulation. See (more...)
(Full Text)
Cell Lines For Angiogenesis Screening
Background:
The National Cancer Institute's Angiogenesis Core Facility is
seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize multicolored fluorescent cell lines and software
for high-throughput (more...)
(Full Text)
Fully Human NKG2D Monoclonal Antibody
Background:
The National Cancer Institute's Experimental Transplantation and
Immunology Branch is seeking statements of capability or interest
from parties interested in collaborative research to further
develop, evaluate, or commercialize human monoclonal antibodies as
therapeutic agents.
Technology:
NKG2D (more...)
(Full Text)
Sugar Substrates For Targeted-Drug Delivery
Background:
The National Cancer Institute's Nanobiology Program is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize the synthesis of UDP derivatives of C2 modified
galactose (more...)
(Full Text)
Human Domain Antibody (dAb) Against HIV-1
Background:
The National Cancer Institute's Center for Cancer Research
Nanobiology Program is seeking statements of capability or interest
from parties interested in collaborative research to further
develop, evaluate, or commercialize antibody-based therapeutics for
HIV.
Technology:
The invention (more...)
(Full Text)
Biomarkers For Birt-Hogg-Dube (BHD) Syndrome And Renal Cancer
Background:
The National Cancer Institute's Urologic Oncology Branch is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize detection methods to screen a biomarker for (more...)
(Full Text)
Method To Treat Numerous Types Of Cancer Using Small Molecule Inhibitors
Background:
The National Cancer Institute's Urologic Oncology Branch is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize small molecule inhibitors of the c-Met signaling
pathway.
Technology:
A (more...)
(Full Text)
Cancer Therapeutic Composed Of Cholera Exotoxin
The National Cancer Institute's Laboratory of Molecular Biology is
seeking parties interested in collaborative research to further
develop, evaluate, or commercialize immunotoxins composed of
cholera exotoxin.
R&D Status: In vitro proof-of-concept
with results similar to (more...)
(Full Text)
DNA Repair Enzymes As Cancer Targets
Background:
The National Cancer Institute's Laboratory of Molecular
Pharmacology is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize inhibitors of human tyrosyl-DNA
phosphodiesterase (Tdp1) as (more...)
(Full Text)
Antibody-Based Cancer Biomarkers And Therapeutic Agents
Background:
The National Cancer Institute's Mammary Biology and Tumorigenesis
Laboratory is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize isoform-specifc antibodies to the human
prolactin (more...)
(Full Text)
Human Monoclonal Antibodies Against The Plague
Background:
The National Cancer Institute's Protein Interactions Group is
seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize therapeutic human monoclonal antibodies directed
against plague (Yersinia (more...)
(Full Text)
Method To Inactivate Viruses For Vaccine Development
Background:
The National Cancer Institute's Nanobiology Program is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize the use of hydrophobic crosslinkers for vaccine
development using (more...)
(Full Text)
cDNA Fragments As Novel Anti-Cancer Therapeutics And Diagnostics
Background:
The National Cancer Institute's Hatfield Clinical Research Center
is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize cDNA fragments as antiangiogenic and antitumor
therapy.
Technology:
This (more...)
(Full Text)
Methods Of Preventing Tissue Ischemia
Background:
The National Cancer Institute's Laboratory of Pathology is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize therapeutics targeting vasodialation.
Technology:
Nitric oxide (NO) plays an (more...)
(Full Text)
Methods For Accurately Measuring And Regulating Adrenomedullin
Background:
The National Cancer Institute's Angiogenesis Core Facility is
seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize methods to detect or regulate adrenomedullin (AM)
levels. (more...)
(Full Text)
Therapeutics To Treat Ocular Diseases
Background:
The National Eye Institute's Section on Epithelial and Retinal
Physiology and Disease (SERPD) is seeking statements of capability
or interest from parties interested in collaborative research to
further develop, evaluate, or commercialize therapeutics (more...)
(Full Text)
Therapeutics Based On The Induced Internalization Of Surface Receptors
Background:
The National Cancer Institute, Laboratory of Cellular Oncology is
seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate,
or commercialize therapeutics for diseases or conditions associated
with (more...)
(Full Text)
Methods To Treat Fatty Liver Disease
Background:
The National Cancer Institute's Laboratory of Metabolism is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize therapeutics for fatty liver disease.
Technology:
Currently, there are (more...)
(Full Text)
Methods To Treat Fatty Liver Disease
Transgenic Mouse Model For Development Of Cancer Therapeutics
Therapeutics Based On The Induced Internalization Of Surface Receptors
TTC maintains an e-mail service to notify you of new Collaborative Opportunities. If you would like to receive these emails, please sign up below. If you'd like to unsubscribe you can use this form as well.